C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 120 filers reported holding C4 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $16,634,885 | -32.7% | 2,819,472 | 0.0% | 0.34% | -40.4% |
| Q3 2022 | $24,727,000 | +6.0% | 2,819,472 | -8.9% | 0.57% | -5.5% |
| Q2 2022 | $23,335,000 | -78.8% | 3,094,825 | -31.7% | 0.60% | -73.5% |
| Q1 2022 | $109,946,000 | +36.9% | 4,531,982 | +81.6% | 2.28% | +94.0% |
| Q4 2021 | $80,338,000 | -27.9% | 2,494,965 | 0.0% | 1.17% | -30.2% |
| Q3 2021 | $111,475,000 | +37.1% | 2,494,965 | +16.1% | 1.68% | +37.0% |
| Q2 2021 | $81,327,000 | +2.4% | 2,149,228 | 0.0% | 1.23% | -1.0% |
| Q1 2021 | $79,437,000 | +15.7% | 2,149,228 | 0.0% | 1.24% | +7.6% |
| Q4 2020 | $68,679,000 | – | 2,149,228 | – | 1.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |